AR and prostate cancer: A previous study has reported that mutation of SUMO-conjugated sites in androgen receptor (AR) may result in an increase of AR transcriptional activity, and hence promoting cell proliferation and hypoxia-induced angiogenesis in Prostate cancer (Lin et al., 2004).